On the horizon
A story about how 2023 will be a ‘transition year’ for COVID-19 vaccines, had readers posting.
The model for such shots will undoubtedly change next year: but what this will look like in terms of key metrics such as number of doses and revenues remains in question.
Both Pfizer and Moderna compare the likely COVID-19 vaccine opportunity to flu volumes, although analysts are less convinced that the uptake will match these expectations.
Photo Credit: GettyImages/Salvatore De Cicco